Kura Oncology, Inc.
KURAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company carries a $802.1M market cap, placing it firmly in the small-cap category. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Market Cap
$802.1M
Beta
0.32
P/E (TTM)
—
P/E (Fwd)
-3.54
EPS (TTM)
$-3.35
EPS (Fwd)
$-2.55
ROE
-124.7%
ROA
-28.4%
Cash
$580.8M
Total Debt
$24.3M
Free CF
-$129.8M
52W Change
40.7%
Annual Financials
Cash vs Debt
With $580.8M in cash and $24.3M in debt, KURA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$129.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -124.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Kura Oncology, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, KURA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KURA.